{"id":127229,"date":"2026-09-07T20:47:25","date_gmt":"2026-09-07T20:47:25","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/127229\/"},"modified":"2026-09-07T20:47:25","modified_gmt":"2026-09-07T20:47:25","slug":"novartis-late-stage-cardiovascular-outcome-study-fails-stock-down-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/127229\/","title":{"rendered":"Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis NVS announced that the late-stage study on investigational candidate, pelacarsen, failed.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Pelacarsen is an investigational antisense oligonucleotide (ASO) designed to potently inhibit lipoprotein (a), Lp(a), production at its source.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis secured global rights from Ionis Pharmaceuticals IONS to develop, manufacture and commercialize pelacarsen under a licensing and collaboration agreement.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Shares of Novartis lost 4.7% in after-hours trading following the results while IONS was down 10%.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Year to date, Novartis shares have gained 16.1% compared with the industry&#8217;s growth of 14.5%.  <\/p>\n<p>    <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/2caebfc770c8f5b1221dfe028890882318d3f197a12a8935870b161c53e3e245\/lightyear_networkapi\/resizefit_w960%3Bquality_80%3Bformat_webp\/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Fzacks.com%2F73ba3918037487414e2296d125bfa358.jpg\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Zacks Investment Research\" height=\"280\" width=\"619\" class=\"yf-1f8hkhu loader\"\/><\/a> Zacks Investment Research           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Image Source: Zacks Investment Research  <\/p>\n<p>        More on NVS&#8217; Late-Stage CVD Study          <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Lp(a)HORIZON is a phase III, randomized, placebo-controlled, double-blind, parallel-group, multi-center global cardiovascular outcomes trial evaluating whether pelacarsen can reduce the incidence of four-point major adverse cardiovascular events in 8,323 patients with elevated lipoprotein(a) [Lp(a)] levels and established cardiovascular disease.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">However, the study did not meet the primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, as compared to placebo.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Elevated Lp(a) is an inherited cardiovascular risk factor that affects approximately one in five people worldwide, with no approved targeted therapies currently available.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Nonetheless, lower lipoprotein (a), Lp(a), levels were achieved with pelacarsen in this study population, which was receiving guideline-directed treatments, including lipid lowering and antihypertensive therapies.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The failure of this late-stage study is a setback for NVS as the company is looking to develop new drugs in wake of generic competition for some of its blockbuster drugs.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Moreover, the targeted market has huge potential and the successful development of pelacarsen would have been a significant boost for the company.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Ionis Pharmaceuticals discovered pelacarsen and led its early development. In February 2019, Novartis exercised its option to license the rights to develop and commercialize pelacarsen as a targeted cardiovascular therapy.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Meanwhile, sales of biotech giant Amgen AMGN too declined 5% in after-hours trading on Sept. 4 following NVS&#8217; announcement.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Investors were probably wary as AMGN is developing olpasiran, best-in-class small interfering ribonucleic acid (siRNA) molecule that reduces lipoprotein(a) (Lp(a)) synthesis in the liver, in late-stage studies.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The failure of NVS&#8217; study on pelacarsen clouds the prospects of AMGN&#8217;s olpasiran as well.  <\/p>\n<p>       Novartis AG Price, Consensus and EPS Surprise            <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis AG price-consensus-eps-surprise-chart | Novartis AG Quote  <\/p>\n<p>       Novartis Looks to Strengthen Portfolio         <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">NVS&#8217; cardiovascular portfolio comprises blockbuster drug Entresto.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">However, generic competition, including the loss of U.S. exclusivity, has adversely impacted Entresto sales of late.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Despite a massive decline in Entresto sales, Novartis delivered a strong second-quarter performance, demonstrating that its portfolio of newer growth products is increasingly capable of offsetting the impact of generic competition for Entresto.<br \/>Oncology drug Promacta is also facing generic competition.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Strong demand for key growth brands, including Kisqali, Kesimpta, Scemblix, Pluvicto and Leqvio, is boosting the top line.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">With 2026 marking the largest patent cliff in the company&#8217;s history, execution remains the key investment theme.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Last week, NVS announced positive top-line results from the late-stage REMODEL-1\/-2 studies on remibrutinib in relapsing multiple sclerosis.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Remibrutinib is a highly selective oral Bruton&#8217;s tyrosine kinase (BTK) inhibitor that blocks the BTK pathway, reducing the activation of B cells and innate immune cells to modulate immune regulatory networks and associated neuroinflammation.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The studies met their primary endpoint, significantly reducing annualized relapse rate versus Aubagio in the targeted patient population.  <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Remibrutinib 25 mg is already approved as Rhapsido by the FDA in September 2025 and the EMA in April 2026 for the treatment of adults with CSU.  <\/p>\n<p>       NVS&#8217; Zacks Rank         <\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis currently carries a Zacks Rank #3 (Hold). You can see the complete list of today&#8217;s Zacks #1 Rank (Strong Buy) stocks here.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. <a href=\"https:\/\/www.zacks.com\/registration\/pfp\/?ALERT=RPT_7BEST_YHOSYND&amp;ADID=SYND_YAHOO_7BEST_ANALYSTBLOG_256_2985965&amp;cid=CS-YAHOO-FT-analyst_blog|company_news_medical_sector-2985965&amp;t=NVS\" data-ylk=\"slk:Click%20to%20get%20this%20free%20report;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Click to get this free report&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Click to get this free report<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/www.zacks.com\/registration\/pfp?ALERT=YAHOO_ZER&amp;d_alert=ZER_CONF&amp;t=NVS&amp;ADID=SYND_YAHOO_TCK_ANALYSTBLOG_256_2985965_NVS&amp;cid=CS-YAHOO-FT-analyst_blog|company_news_medical_sector-2985965\" data-ylk=\"slk:Novartis%20AG%20(NVS)%20%3A%20Free%20Stock%20Analysis%20Report;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Novartis AG (NVS) : Free Stock Analysis Report&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Novartis AG (NVS) : Free Stock Analysis Report<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/www.zacks.com\/registration\/pfp?ALERT=YAHOO_ZER&amp;d_alert=ZER_CONF&amp;t=AMGN&amp;ADID=SYND_YAHOO_TCK_ANALYSTBLOG_256_2985965_AMGN&amp;cid=CS-YAHOO-FT-analyst_blog|company_news_medical_sector-2985965\" data-ylk=\"slk:Amgen%20Inc.%20(AMGN)%20%3A%20Free%20Stock%20Analysis%20Report;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Amgen Inc. (AMGN) : Free Stock Analysis Report&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Amgen Inc. (AMGN) : Free Stock Analysis Report<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/www.zacks.com\/registration\/pfp?ALERT=YAHOO_ZER&amp;d_alert=ZER_CONF&amp;t=IONS&amp;ADID=SYND_YAHOO_TCK_ANALYSTBLOG_256_2985965_IONS&amp;cid=CS-YAHOO-FT-analyst_blog|company_news_medical_sector-2985965\" data-ylk=\"slk:Ionis%20Pharmaceuticals%2C%20Inc.%20(IONS)%20%3A%20Free%20Stock%20Analysis%20Report;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Ionis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Ionis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/www.zacks.com\/stock\/news\/2985965\/novartis-late-stage-cardiovascular-outcome-study-fails-stock-down?cid=CS-YAHOO-FT-analyst_blog|company_news_medical_sector-2985965&amp;t=NVS\" data-ylk=\"slk:This%20article%20originally%20published%20on%20Zacks%20Investment%20Research%20(zacks.com).;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;This article originally published on Zacks Investment Research (zacks.com).&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">This article originally published on Zacks Investment Research (zacks.com).<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/www.zacks.com\/?t=NVS&amp;cid=CS-YAHOO-FT-analyst_blog|company_news_medical_sector-2985965\" data-ylk=\"slk:Zacks%20Investment%20Research;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Zacks Investment Research&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Zacks Investment Research<\/a>  <\/p>\n","protected":false},"excerpt":{"rendered":"Novartis NVS announced that the late-stage study on investigational candidate, pelacarsen, failed. Pelacarsen is an investigational antisense oligonucleotide&hellip;\n","protected":false},"author":2,"featured_media":127230,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[45700,3713,28740,206,1078,62065,62066,62028,9959,57008,472],"class_list":["post-127229","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-amgn","tag-entresto","tag-ionis-pharmaceuticals","tag-novartis","tag-novartis-ag","tag-novartis-ag-price","tag-novartis-ag-quote","tag-novartis-nvs","tag-nvs","tag-pelacarsen","tag-zacks-investment-research"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117231723779821746","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/127229","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=127229"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/127229\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/127230"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=127229"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=127229"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=127229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}